Pembrolizumab (Keytruda) Injection from Canada

Pembrolizumab targets PD-1 for advanced cancer immunotherapy like Hodgkin lymphoma. HTS 3002.15.00.11 covers this monoclonal antibody immunological product in pre-filled syringes for retail therapeutic use.

Duty Rate — Canada → United States

0%

Rate breakdown

9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter

Import Tips

Include BLA number and monoclonal sequence data in entry summary

Monitor for counterfeit risks; use serialized packaging verification